# Harbour BioMed Appoints Dr. Luisa Salter-Cid as Scientific Advisor

- Link: https://www.thailand-business-news.com/pr-news/harbour-biomed-appoints-dr-luisa-salter-cid-as-scientific-advisor
- Published: 2026-06-11T08:52:00+07:00
- Author: PR Newswire

|   |

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 11, 2026 /PRNewswire/—
Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company 
committed to the discovery and development of novel antibody therapeutics in immunology,
oncology and other disease areas, today announced the appointment of Dr. Luisa Salter-
Cid as Scientific Advisor.

Dr. Salter-Cid brings over 20 years of outstanding leadership experience in the 
biotech and pharmaceutical industries, having held senior executive roles at Flagship
Pioneering, Bristol Myers Squibb (BMS), and Gossamer Bio. Her expertise spans Immunology
and Immuno-Oncology, where she has established a prolific track record of translating
scientific insights into clinical-stage assets.

Dr. Salter-Cid currently serves as Venture Partner at Osage University Partners (
OUP), a premier venture capital firm focused on investing in startups that commercialize
university research. Prior to that, she served as Chief Scientific Officer of Pioneering
Medicines at Flagship Pioneering, where she was responsible for pioneering a portfolio
of groundbreaking medicines sourced from the broad spectrum of scientific platforms
within the Flagship ecosystem. Before joining Flagship, she served as Chief Scientific
Officer at Gossamer Bio, where she was instrumental in building the company’s portfolio
of immunology and immuno-oncology programs.

Dr. Salter-Cid’s tenure at Bristol Myers Squibb further highlights her outstanding
capabilities. During her 13 years there, she most recently served as Vice President
and Head of Immunology, Small Molecule Immuno-Oncology, and Genomics Discovery. 
In this capacity, she led teams that successfully advanced over 20 compounds into
clinical development, demonstrating her outstanding ability to drive innovation 
from discovery to the clinic. Throughout her career, Dr. Salter-Cid has authored
more than 90 publications and patents.

"We are thrilled to welcome Dr. Salter-Cid to our Scientific Advisory Board," said
Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed. "Her outstanding,
deep expertise in immunology and immuno-oncology, combined with her proven track
record of advancing novel therapies through development, will be invaluable as we
continue to expand our pipeline of differentiated antibody therapeutics. Her strategic
insights into next-generation drug development will significantly bolster our efforts
to address unmet medical needs globally."

"I am honored to join Harbour BioMed as a Scientific Advisor," said Dr. Salter-Cid."
Harbour BioMed has established a unique and powerful position in the industry with
its world-leading Harbour Mice^(®) technology platform and a growing pipeline of
promising therapeutics. I look forward to collaborating with the team to help advance
their cutting-edge science and strategic vision to bring life-saving medicines to
patients."

**About Harbour BioMed**

Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to 
the discovery and development of novel antibody therapeutics in immunology, oncology
and other areas. The Company is building a robust portfolio and differentiated pipeline
through internal R&D capability, strategic global collaborations in co-discovery
and co-development, and selective acquisitions.

Our proprietary antibody technology platform, Harbour Mice^(®), generates fully 
human monoclonal antibodies in both the conventional two heavy and two light chain(
H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies,
the HCAb-based immune cell engagers (HBICE^(®)) bispecific antibody technology enables
tumor-killing effects that traditional combination therapies cannot achieve. The
HCAb-based Antibody Plus technology (HCAb PLUS^(TM)) provides comprehensive modality
solutions for the development of innovative multi-specific medicines in different
disease areas. Additionally, building upon the Harbour Mice^(®) platform, Harbour
BioMed launched its first fully human Generative AI HCAb Model powered by its Hu-
mAtrIx^(TM) AI platform, accelerating the development of innovative therapies.

By integrating Harbour Mice^(®), HBICE^(®), HCAb PLUS^(TM), a single B-cell cloning
platform and AI technologies, Harbour BioMed has built a highly efficient and distinctive
antibody discovery engine for developing next-generation therapeutic antibodies.
For more information, please visit [www.harbourbiomed.com](https://www.harbourbiomed.com/).

 

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Harbour BioMed Appoints Dr. Luisa Salter-Cid as Scientific Advisor ](http://www.prnasia.com/story/archive/4981334_CN81334_0?rand=184833)
